Skip to main content
. Author manuscript; available in PMC: 2026 Aug 27.
Published in final edited form as: Neurosci Lett. 2026 Aug 5;885:138703. doi: 10.1016/j.neulet.2026.138703

Fig. 1. Xylazine (XYL) reduced spontaneous locomotor activity and METH-evoked hyperlocomotion.

Fig. 1.

Locomotor activity was measured 90 min after (A-C) XYL (0, 1, 2.5, 5 mg/kg) injection or (D-F) co-administration of XYL (2.5 mg/kg) and METH (1 mg/kg). Each data set includes the 90-min time course, the first 30 min post-injection, and cumulative 90-min post-injection. (A-C): XYL by itself: p < 0.05 versus XYL (0) (vehicle) for (B) 30-min interval. n = 8-10/group (shown under bars). (D-F): XYL + METH: p < 0.05, p < 0.01, or p < 0.0001 versus XYL (0) (vehicle + METH) group for (E) 30-min and (F) 90-min intervals. n = 7-8/group.